Literature DB >> 7687164

Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology.

T H Que1, J G Marco, J Ellis, E Matutes, V B Babapulle, S Boyle, D Catovsky.   

Abstract

Fluorescence in situ hybridization (FISH) with a chromosome 12 specific alpha-centromeric probe was performed on interphase cells from 183 patients with B-cell chronic lymphocytic leukemia (CLL). Twenty one cases with trisomy 12 (11.5%) were detected. The number of trisomic cells ranged from 5.5% to 76% (mean 38.5%). No correlation was found between the presence of trisomy 12 and white blood cell count, hemoglobin level, platelet count, a specific immunophenotype, clinical stage, sex, splenomegaly, or lymphadenopathy. Morphologic review of all cases with trisomy 12 showed seven (33%) with more than 10% prolymphocytes and three (14%) with CLL of mixed cell type. While trisomy 12 is the most common chromosomal abnormality in CLL, it is more frequent in morphologically atypical cases, some of which may be undergoing transformation. There was a statistically significant difference in the incidence of atypical cases between those with (47%) and without (7.6%) trisomy 12 (P < .001). It remains to be determined whether this abnormality is associated with a worse prognosis; this is currently being investigated in the context of a national therapeutic trial. The technique used is more sensitive than conventional cytogenetic analysis, which in this series failed to detect trisomy 12 in six cases. FISH allows the systematic study on a large number of patients without the need of metaphase preparations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687164

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

Review 2.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 3.  Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia.

Authors:  Russell A Higgins; Shelly R Gunn; Ryan S Robetorye
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 4.  Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia.

Authors:  Gábor Méhes
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

5.  Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Authors:  Paolo Strati; Lynne V Abruzzo; William G Wierda; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-11

6.  A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.

Authors:  Walid Al Achkar; Abdulsamad Wafa; Bashar Yousef Ali; Marina Manvelyan; Thomas Liehr
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

7.  Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.

Authors:  John C Riches; Conor J O'Donovan; Sarah J Kingdon; Fabienne McClanahan; Andrew J Clear; Donna S Neuberg; Lillian Werner; Carlo M Croce; Alan G Ramsay; Laura Z Rassenti; Thomas J Kipps; John G Gribben
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

Review 8.  Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.

Authors:  G Juliusson
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 9.  Clinical experience with fludarabine in leukaemia.

Authors:  M J Keating; E Estey; S O'Brien; H Kantarjian; L E Robertson; W Plunkett
Journal:  Drugs       Date:  1994       Impact factor: 9.546

10.  MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Authors:  Masato Ito; Shinsuke Iida; Hiroshi Inagaki; Kazuya Tsuboi; Hirokazu Komatsu; Motoko Yamaguchi; Naoya Nakamura; Ritsuro Suzuki; Masao Seto; Shigeo Nakamura; Yasuo Morishima; Ryuzo Ueda
Journal:  Jpn J Cancer Res       Date:  2002-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.